Overview

Safety and Tolerability of NN9068 in Healthy Male Volunteers

Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
This trial is conducted in Europe. The aim of this clinical trial is to investigate the safety, tolerability, level of drug exposure and effect of NN9068. The trial participants will be randomised to 4 different treatments in trial, receiving trial products in a pre-defined order.
Phase:
Phase 1
Details
Lead Sponsor:
Novo Nordisk A/S
Treatments:
Insulin
Insulin, Globin Zinc
Insulin, Long-Acting
Liraglutide
Xultophy